Literature DB >> 21751348

Identification of direct targets for the miR-17-92 cluster by proteomic analysis.

Hirotaka Kanzaki1, Sachio Ito, Hiroko Hanafusa, Yoshimi Jitsumori, Seiji Tamaru, Kenji Shimizu, Mamoru Ouchida.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally repress the expression of target genes. Many miRNAs have been implicated in a number of diseases, including cancers. The miR-17-92 miRNA cluster is known as a body of oncogenic miRNAs, and has been shown to be overexpressed in several cancers, including lung cancer. Although the overexpression of miR-17-92 is clearly implicated in the development of lung cancer, only a few direct targets for the miR-17-92 cluster have been identified thus far. In this study, we examined miR-17-92 target profiles in SBC-3 small-cell lung cancer cells using a quantitative proteomic strategy to identify direct targets of the miR-17-92 cluster. By knocking down the expression of endogenous miR-19a, miR-20a and miR-92-1, which are contained in the cluster, 112 up-regulated proteins were detected and also identified as potential targets of these miRNAs. Among these candidate targets, we validated one direct target, RAB14. In conclusion, these findings suggest that proteomic approaches are valuable for identifying direct miRNA targets, and we were able to identify a novel direct target for the miR-92-1 using our proteomic strategy.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21751348     DOI: 10.1002/pmic.201000501

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  16 in total

Review 1.  Modulation of polycystic kidney disease by non-coding RNAs.

Authors:  Harini Ramalingam; Matanel Yheskel; Vishal Patel
Journal:  Cell Signal       Date:  2020-01-23       Impact factor: 4.315

2.  MicroRNAs in the axon locally mediate the effects of chondroitin sulfate proteoglycans and cGMP on axonal growth.

Authors:  Yi Zhang; Michael Chopp; Xian Shuang Liu; Haifa Kassis; Xinli Wang; Chao Li; Guangning An; Zheng Gang Zhang
Journal:  Dev Neurobiol       Date:  2015-06-24       Impact factor: 3.964

Review 3.  MicroRNAs and lung cancers: from pathogenesis to clinical implications.

Authors:  Ji Qi; David Mu
Journal:  Front Med       Date:  2012-04-18       Impact factor: 4.592

4.  Evaluation of the mirn23a Cluster through an iTRAQ-based Quantitative Proteomic Approach.

Authors:  Katelyn R Ludwig; Richard Dahl; Amanda B Hummon
Journal:  J Proteome Res       Date:  2016-04-06       Impact factor: 4.466

Review 5.  Proteomics for understanding miRNA biology.

Authors:  Tai-Chung Huang; Sneha M Pinto; Akhilesh Pandey
Journal:  Proteomics       Date:  2012-12-27       Impact factor: 3.984

6.  miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

Authors:  Yuanzheng Yang; Gangxiong Huang; Zhichao Zhou; Jason G Fewell; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2017-10-27       Impact factor: 6.261

7.  MicroRNAs - Important Molecules in Lung Cancer Research.

Authors:  Petra Leidinger; Andreas Keller; Eckart Meese
Journal:  Front Genet       Date:  2012-01-23       Impact factor: 4.599

8.  Mechanistic Roles of Noncoding RNAs in Lung Cancer Biology and Their Clinical Implications.

Authors:  Katey S S Enfield; Larissa A Pikor; Victor D Martinez; Wan L Lam
Journal:  Genet Res Int       Date:  2012-07-18

9.  Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach.

Authors:  Mamoru Ouchida; Hirotaka Kanzaki; Sachio Ito; Hiroko Hanafusa; Yoshimi Jitsumori; Seiji Tamaru; Kenji Shimizu
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

10.  miR-17-5p regulates endocytic trafficking through targeting TBC1D2/Armus.

Authors:  Andrius Serva; Bettina Knapp; Yueh-Tso Tsai; Christoph Claas; Tautvydas Lisauskas; Petr Matula; Nathalie Harder; Lars Kaderali; Karl Rohr; Holger Erfle; Roland Eils; Vania Braga; Vytaute Starkuviene
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.